Acrivon Therapeutics is a biotech company specializing in drug development through early clinical treatment success using our unique predictive biomarker approach. Our technology platform is based on integrating drug-regulated, global proteomics with focused intact tissue digital imaging to develop drug-tailored biomarker signatures for prospective patient responder identification. The foundational science is based on proven, pathway-based methods linking active disease-driving mechanisms with the drug mechanism-of-action, to precisely match the therapy with patients who will benefit. Our method is applicable across drug modalities.
- Peter Blume-Jensen, MD, PhD Co-Founder, President & CEO
- Kristina Masson, PhD Co-Founder & Global Head of Operations
- Michail (Misha) Shipitsin, PhD Director, Head of Biomarker Development